 Outlook Therapeutics, Inc. OTLK the Company, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today provided a clinical update for ONS-5010 LYTENAVATM bevacizumab-vikg, the Companys investigational ophthalmic formulation of bevacizumab. Outlook Therapeutics is currently conducting two registration clinical trials for ONS-5010. 